Double Medical Technology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jan '22 Jan 1, 2022
Operating Revenue	2,672	2,581	2,119	1,525	1,428	1,989
Other Revenue	19.85	19.85	16.7	8.39	5.94	5.02
Revenue	2,692	2,601	2,136	1,533	1,434	1,994
Revenue Growth (YoY)	19.19%	21.79%	39.30%	6.91%	-28.09%	25.68%
Cost of Revenue	824.8	826.15	710.15	541.52	344.6	319.12
Gross Profit	1,867	1,775	1,425	991.6	1,089	1,675
Selling, General & Admin	861.92	844.75	769.03	690.5	788.18	746.94
Research & Development	333.69	331.2	306.87	285.28	256.72	167.07
Other Operating Expenses	28.06	26.41	10.98	-2.51	15.77	27.52
Operating Expenses	1,223	1,204	1,093	972.13	1,059	957.77
Operating Income	643.86	571.15	332.5	19.47	30.9	717.45
Interest Expense	-5.36	-6.18	-6.49	-7.16	-3.1	-0.55
Interest & Investment Income	32.53	32.21	44.78	39.65	37.23	34.63
Currency Exchange Gain (Loss)	10.25	10.25	-11.35	0.77	7.62	-5.87
Other Non Operating Income (Expenses)	-20.94	-1.67	-0.16	-0.54	-0.32	-0.2
EBT Excluding Unusual Items	660.34	605.76	359.28	52.19	72.33	745.45
Impairment of Goodwill	-5.91	-5.91	-0.5	-0.86	-1.37	-0.91
Gain (Loss) on Sale of Investments	57.71	49.41	3.11	5.6	1.77	1.22
Gain (Loss) on Sale of Assets	0.07	0.62	0.27	0.3	-1.73	-0
Asset Writedown	-6.22	-0.35	-0.43	-0.02	-0.54	-0.03
Legal Settlements	-2.8	-2.8	-	-	-	-19.1
Other Unusual Items	83.06	83.3	66.69	42.51	77	75.88
Pretax Income	786.25	730.04	428.41	99.72	147.46	802.51
Income Tax Expense	100.02	93.17	43.12	13.4	37.89	111.01
Earnings From Continuing Operations	686.23	636.88	385.29	86.32	109.57	691.5
Minority Interest in Earnings	-43.13	-37.25	-28.49	-27.36	-17.01	-18.19
Net Income	643.1	599.63	356.8	58.96	92.56	673.31
Net Income to Common	643.1	599.63	356.8	58.96	92.56	673.31
Net Income Growth	61.51%	68.06%	505.16%	-36.30%	-86.25%	11.16%
Shares Outstanding (Basic)	407	408	415	421	421	401
Shares Outstanding (Diluted)	407	408	415	421	421	403
Shares Change (YoY)	-2.05%	-1.68%	-1.49%	0.10%	4.35%	0.52%
EPS (Basic)	1.58	1.47	0.86	0.14	0.22	1.68
EPS (Diluted)	1.58	1.47	0.86	0.14	0.22	1.67
EPS Growth	64.89%	70.93%	514.29%	-36.36%	-86.83%	10.60%
Free Cash Flow	731.11	697.83	171.84	-231.82	-156.63	438.15
Free Cash Flow Per Share	1.80	1.71	0.41	-0.55	-0.37	1.09
Dividend Per Share	0.600	0.600	0.500	0.250	-	0.500
Dividend Growth	20.00%	20.00%	100.00%	-	-	-37.50%
Gross Margin	69.36%	68.23%	66.75%	64.68%	75.97%	84.00%
Operating Margin	23.92%	21.96%	15.57%	1.27%	2.15%	35.97%
Profit Margin	23.89%	23.05%	16.71%	3.85%	6.45%	33.76%
Free Cash Flow Margin	27.16%	26.83%	8.05%	-15.12%	-10.92%	21.97%
EBITDA	771.56	696.35	447.72	121.28	117.12	782.07
EBITDA Margin	28.66%	26.77%	20.96%	7.91%	8.17%	39.22%
D&A For EBITDA	127.7	125.2	115.22	101.81	86.22	64.62
EBIT	643.86	571.15	332.5	19.47	30.9	717.45
EBIT Margin	23.92%	21.96%	15.57%	1.27%	2.15%	35.97%
Effective Tax Rate	12.72%	12.76%	10.06%	13.44%	25.70%	13.83%
Revenue as Reported	2,692	2,601	2,136	1,533	1,434	1,994

Source: S&P Global Market Intelligence. Standard template. Financial Sources.